| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| ZVRA | ZVRA | Shares | USD | XNGS |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| ZVRA | ZVRA | Shares | USD | XNGS |
Zevra Therapeutics, Inc. develops therapeutics for patients with rare diseases, focusing on conditions such as Niemann-Pick disease type C and urea cycle disorders. The company aims to address unmet medical needs through scientific advancements and is engaged in clinical trials to bring its products, including MIPLYFFA® and OLPRUVA®, to market. Zevra operates primarily in the biotechnology sector, targeting patients and caregivers affected by rare diseases.
No recent RNS announcements for ZVRA across ZVRA.
No recent RNS announcements for ZVRA across ZVRA.